Innova Captab Limited share price
NSE: INNOVACAP · ISIN INE0DUT01020
Key numbers
- Market cap
- ₹ 7,331 Cr
- Current price
- ₹ 1,281.00
- 52-week high / low
- ₹ 1,354 / 622
- Stock P/E
- 47.6
- Book value
- ₹ 190.6
- Dividend yield
- 0.31%
- ROCE
- 15.0%
- ROE
- 13.7%
- Debt to equity
- 0.32
- Sales growth (3 yrs)
- 20.1%
- Profit growth (3 yrs)
- 27.5%
- 1-year return
- 47.3%
About Innova Captab Limited
Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs and pharmaceutical products in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, antispasmodic, antifibrinolytic, cardiovascular, antioxidant and vitamins, antihyperuricemia and antigout, fluoroquinolone and macrolide, nootropics and neurotonics/neurotrophics, antiulcerative, antimalarial anxiolytic, anticonvulsant and antipsychotic, bladder and prostate disorder, antifungal, anthelmintic and antiviral, anticholinergic, anti-asthmatic, and bronchodilator products in the form of tablets, capsules, dry syrups, dry powder injection, ointments, and liquid orals. The company sells its branded generic products through a network of distributors, stockists, and pharmacies, as well as online channels in various e-commerce…
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 352 | 380 | 450 | 448 | 471 |
| Operating profit | 52 | 52 | 69 | 65 | 73 |
| Net profit | 31 | 30 | 42 | 38 | 44 |
| EPS (₹) | 5.42 | 5.18 | 7.37 | 6.65 | 7.71 |
Concall summary (2026-08-14)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- The performance is broadly in line with growth trajectory we have outlined in the year and provided -- provides further confidence in our ability to deliver on our guidance of 20% revenue growth and profitability outpac e revenue for FY27.
- The CDMO business reported revenue of INR328 crores during Q1 FY27, reflecting a year -on-year growth of 32%.
Growth & demand
- Consolidated revenue for the quarter stood at INR470.9 crores, registering a strong 34% year - on-year growth supported by strong demand across both our business areas.
- So, volume growth, at overall level on a revenue basis, if I break this growth into two parts, volume is around 20% to 22% growth year -on-year at an overall manufacturing capability level.
Margins & costs
- Innova Captab Limited August 12, 2026 On the profitability side, EBITDA for the quarter stood at INR75.1 crores, a growth of 33% year-on-year with a margin of 16%.
- Sir just on the margin bridge, so Jammu margin is about 1 % to 1.5% which means non-Jammu margin is plus 20%.
Capex & expansion
- So, if I see this quarter at an annualized basis, we are looking at a capacity utilization of around 25% to 30% on an annualized basis, based on the performance of this particular quarter.
- When we done the INR500 crores capex that time let's say the ex -Jammu capex was also like a INR500 crores.
Balance sheet & cash
- My first question is regarding the networking capital, like management was like aiming for the historical level following the Jammu ramp -up.
- So, see, as far as our Jammu ramp-up is concerned, the initial working capital has already been built up and factored in our initial ramping days previous year itself.
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.